Shanghai Rightongene Biotechnology Co., Ltd. (SHSE: 688217)
Health Care · Biotechnology · CN
CN¥24.70
+6.51% today · -17.9% 1Y
Shanghai Rightongene Biotechnology Co., Ltd. (SHSE: 688217) operates in the Biotechnology industry within the Health Care sector. The company is valued at $202.10M.
Over the last twelve months the share price has lost 17.9%, trading between 17.81 and 36.00.
Tweenvest scores Shanghai Rightongene Biotechnology Co., Ltd. across four factors: quality 66/100, value 37/100, growth 0/100, dividend 51/100. Its strongest factor is quality.
688217 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $202.10M
- Revenue (TTM)
- $23.60M
- P/E
- —
- EPS
- -1.06
- Dividend yield
- 1.38%
- Beta (5Y)
- 0.35
- 52-week high
- CN¥36.00
- 52-week low
- CN¥17.81
- Avg volume (3M)
- —
- Shares outstanding
- 55.19M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.85 | +0.34% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.74 | +0.09% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.56 | +0.30% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.19 | +0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $842.16 | +0.97% |
| argenx SEENXTBR: ARGX | $65.85B | €880.20 | -2.42% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.47 | -1.10% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.